Clinical Trial

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine how two different doses of cannabidiol (CBD), given as a hemp product, change the blood concentrations of the drug clopidogrel in the body. Results will be used to help design future studies and to assist healthcare providers in informing their patients about the safe use of CBD.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-15.
Trial Details
NCT Number NCT06692933
Lead Sponsor Washington State University
Collaborators: Office of Dietary Supplements (ODS), National Center for Complementary and Integrative Health (NCCIH)
Conditions Interaction
Enrollment 24 participants
Start Date 2024-06-20
Primary Completion 2027-08-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-04